Lifeline for kids with severe bowel disease: compassionate access to unapproved drug
NCT ID NCT06856135
Summary
This program provides continued access to an investigational drug called vedolizumab for children and teenagers with moderate to severe ulcerative colitis or Crohn's disease. It is for participants who were already benefiting from the drug in a previous clinical study and have no good alternative treatments available. The goal is to allow these young patients to keep receiving the medication until it becomes commercially available in the United States.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Center for Digestive Healthcare
AVAILABLEAtlanta, Georgia, 30342, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seattle Children's Hospital
AVAILABLESeattle, Washington, 98105, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California San Francisco
AVAILABLESan Francisco, California, 94158, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.